Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Reviews in Allergy & Immunology
Published in: Clinical Reviews in Allergy & Immunology 2-3/2010

01-04-2010

Mycobacterium Tuberculosis, Autoimmunity, and Vitamin D

Authors: Yinon Shapira, Nancy Agmon-Levin, Yehuda Shoenfeld

Published in: Clinical Reviews in Allergy & Immunology | Issue 2-3/2010

Login to get access

Abstract

Mycobacterium tuberculosis (TB) is a major cause of morbidity and mortality worldwide. Current anti-TB chemotherapies, although effective, are associated with side effects and are limited in treating drug-resistant strands. Autoimmune diseases are a leading cause of morbidity and mortality, with a growing mass of evidence implicating infections (e.g., TB) as their triggers. The burden of TB might further increase by reactivation threats hovering over millions harboring latent infection, thus, calling for novel approaches for this dire ailment. In recent years, the non-calcemic physiological actions of vitamin D have drawn a great deal of attention. In this review, we will focus on the role of vitamin D in the innate immune defense against TB on the one hand and conversely on the immunomodulatory effects of vitamin D on autoimmunity. Taken together, the suggested dual role of vitamin D in treating TB infection and possibly preventing associated autoimmunity will constitute the basis of the current review.
Literature
1.
Koch R (1882) Die aetiologie der tuberculose. Berl Klinische Wochenschr 19:221–230
2.
Mathema B, Kurepina N, Bifani P, Kreiswirth B (2006) Molecular epidemiology of tuberculosis: current insights. Clin Microbiol Rev 19:658–685PubMed
3.
Maartens G, Wilkinson R (2007) Tuberculosis. Lancet 370:2030–2043PubMed
4.
WHO (2008) Global tuberculosis control: surveillance, planning, financing: WHO report. WHO, Geneva WHO/HTM/TB/2008.393
5.
Dye C, Scheele S, Dolin P, Pathania V, Raviglione M (1999) Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country [consensus statement]. WHO Global Surveillance and Monitoring Project. JAMA 282:677–686PubMed
6.
Comstock GW (1982) Epidemiology of tuberculosis. Am Rev Respir Dis 125:128
7.
Iseman M, Madsen L (1989) Drug-resistant tuberculosis. Clin Chest Med 10:341–353PubMed
8.
WHO (2008) Anti-tuberculosis drug resistance in the world: WHO Fourth Global Report. WHO, Geneva WHO/HTM/TB/2008.394
9.
Harel M, Shoenfeld Y (2006) Predicting and preventing autoimmunity, myth or reality? Ann NY Acad Sci 1069:322–345PubMed
10.
Shoenfeld Y, Isenberg DA (1989) The mosaic of autoimmunity. Immunol Today 10:123–126PubMed
11.
Shoenfeld Y, Blank M, Abu-Shakra M, Amital H, Barzilai O, Berkun Y, Bizzaro N, Gilburd B, Zandman-Goddard G, Katz U, Krause I, Langevitz P, Mackay IR, Orbach H, Ram M, Sherer Y, Toubi E, Gershwin ME (2008) The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases. Isr Med Assoc J 10:13–19PubMed
12.
Shoenfeld Y, Zandman-Goddard G, Stojanovich L, Cutolo M, Amital H, Levy Y, Abu-Shakra M, Barzilai O, Berkun Y, Blank M, de Carvalho JF, Doria A, Gilburd B, Katz U, Krause I, Langevitz P, Orbach H, Pordeus V, Ram M, Toubi E, Sherer Y (2008) The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases. Isr Med Assoc J 10:8–12PubMed
13.
Shoenfeld Y, Gilburd B, Abu-Shakra M, Amital H, Barzilai O, Berkun Y, Blank M, Zandman-Goddard G, Katz U, Krause I, Langevitz P, Levy Y, Orbach H, Pordeus V, Ram M, Sherer Y, Toubi E, Tomer Y (2008) The mosaic of autoimmunity: genetic factors involved in autoimmune diseases. Isr Med Assoc J 10:3–7PubMed
14.
Shoenfeld Y, Isenberg D (1988) Mycobacteria and autoimmunity. Immunol Today 9:178–182PubMed
15.
Elkayam O, Caspi D, Lidgi M, Segal R (2007) Auto-antibody profiles in patients with active pulmonary tuberculosis. Int j Tuberc Lung Dis 11:306–310PubMed
16.
Adams J, Hewison M (2008) Unexpected actions of vitamin-D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab 4:80–90PubMed
17.
Arnson Y, Amital H, Shoenfeld Y (2007) Vitamin-D and autoimmunity: new aetiological and therapeutic considerations. Ann Rheum Dis 66:1137–1142PubMed
18.
Martineau A, Wilkinson R, Katalin A, Wilkinson R et al (2007) A single dose of vitamin-D enhances immunity to mycobacteria. Am J Respir Crit Care Med 176:208–213PubMed
19.
Nursyam E, Amin Z, Rumende C (2006) The effect of vitamin-D as supplementary treatment in patients with moderately advanced pulmonary tuberculous lesion. Acta Med Indones 38:3–5PubMed
20.
Institute of Medicine (1997) Dietary reference intakes for calcium, magnesium, phosphorus, vitamin-D, and fluoride. National Academy, Washington, DC
21.
22.
Gibney KB, MacGregor L, Leder K et al (2008) Vitamin D deficiency is associated with tuberculosis and latent tuberculosis infection in immigrants from sub-Saharan Africa. Clin Infect Dis 46:443–446PubMed
23.
Holick M, Chen T (2008) Vitamin-D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 87:1080S–1086SPubMed
24.
Holick M (2008) Deficiency of sunlight and vitamin-D. BMJ 336:1318–1319PubMed
25.
Zittermann A (2003) Vitamin-D in preventive medicine: are we ignoring the evidence? Br J Nutr 89:552–572PubMed
26.
Strachan D, Powell K, Thaker A, Millard F, Maxwell J (1995) Vegetarian diet as a risk factor for tuberculosis in immigrant south London Asians. Thorax 50:175–180PubMed
27.
Nnoaham K, Clarke A (2008) Low serum vitamin-D levels and tuberculosis: a systematic review and meta-analysis. Int J Epidemiol 37:113–119PubMed
28.
Sita-Lumsden A, Lapthorn G, Swaminathan R, Milburn H (2007) Reactivation of tuberculosis and vitamin-D deficiency: the contribution of diet and exposure to sunlight. Thorax 62:1003–1007PubMed
29.
Bellamy R, Ruwende C, Corrah T, McAdam K et al (1999) Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin-D receptor gene. J Infect Dis 179:721–724PubMed
30.
Selvaraj P, Chandra G, Kurian S, Reetha A, Narayanan P (2003) Association of vitamin-D receptor gene variants of Bsm I, Apa I and Fok I polymorphisms with susceptibility or resistance to pulmonary tuberculosis. Curr Sci 84:1564–1568
31.
Bornman L, Campbell S, Fielding K et al (2004) Vitamin-D receptor polymorphisms and susceptibility to tuberculosis in West Africa: a case-control and family study. J Infect Dis 190:1631–1641PubMed
32.
Wilbur A, Kubatko L, Hurtado A, Hill K (2007) Stone A. Vitamin-D receptor gene polymorphisms and susceptibility M. tuberculosis in Native Paraguayans. Tuberculosis 87:329–337PubMed
33.
Lewis S, Baker I, Davey S (2005) Meta-analysis of vitamin-D receptor polymorphisms and pulmonary tuberculosis risk. Int J Tuberc Lung Dis. 9:1174–1177PubMed
34.
Wilkinson R, Llewelyn M, Toossi Z, Patel P et al (2000) Influence of vitamin-D deficiency and vitamin-D receptor polymorphisms on susceptibility to tuberculosis amongst Gujarati Asians in west London: a case-control study. Lancet 355:618–621PubMed
35.
Selvaraj P, Alagarasu K, Harishankar M, Vidyarani M, Narayanan P (2008) Regulatory region polymorphisms of vitamin-D receptor gene in pulmonary tuberculosis patients and normal healthy subjects of south India. Int J Immunogenetics 35:251–254
36.
Ralph A, Kelly P, Anstey N (2008) L-arginine and vitamin-D: novel adjunctive immunotherapies in tuberculosis. Trends Microbiol 16(7):336–344PubMed
37.
Williams CJB (1849) Cod liver oil in phthisis. London J Med 1:1–18
38.
Charpy J (1950) Quelques traitments vitamin´es ou par substances fonctionelles en dermatologie. Bull M´ed 24:505
39.
Martineau A, Honecker F, Wilkinson R, Griffiths C (2007) Vitamin-D in the treatment of pulmonary tuberculosis. J Steroid Biochem Mol Biol 103:793–798PubMed
40.
Liu P, Krutzik S, Modlin R (2007) Therapeutic implications of the TLR and VDR partnership. Trends Mol Med 13:117–124PubMed
41.
Cosma C, Sherman D, Ramakrishnan L (2003) The secret lives of the pathogenic mycobacteria. Annu Rev Microbiol 57:641–676PubMed
42.
Rook G, Steele J, Fraher L et al (1986) Vitamin-D3, γ interferon, and control of proliferation of Mycobacterium tuberculosis by human monocytes. Immunology 57:159–163PubMed
43.
Crowle A, Ross E, May M (1987) Inhibition by 1, 25(OH)2-vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages. Infect Immun 55:2945–2950PubMed
44.
Liu P, Stenger S, Wenzel H et al (2006) Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311:1770–1773PubMed
45.
Adams J (2006) Vitamin-D as a defensin. J Musculoskelet Neuronal Interact 6:344–346PubMed
46.
Martineau A, Wilkinson K, Newton S et al (2007) IFN-γ- and TNF-independent vitamin-D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J Immunol 178:7190–7198PubMed
47.
Liu P, Stenger S, Tang D, Modli R (2007) Cutting edge: Vitamin-D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol 179:2060–2063PubMed
48.
Brightbill H, Libraty D, Krutzik S et al (1999) Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 285:732–736PubMed
49.
Centers for Disease Control and Prevention (CDC) (2007) Trends in tuberculosis—United States. MMWR Morb Mortal Wkly Rep 57:281–285 2008
50.
Ferrari G, Langen H, Naito M, Pieters J (1999) A coat protein on phagosomes involved in the intracellular survival of mycobacteria. Cell 97:435–447PubMed
51.
Pieters J (2001) Evasion of host cell defense mechanisms by pathogenic bacteria. Curr Opin Immunol 13:37–44PubMed
52.
Anand P, Kaul D (2003) Vitamin-D3-dependent pathway regulates TACO gene transcription. Biochem Biophys Res Commun 310:876–877PubMed
53.
Anand P, Kaul D, Sharma M (2008) Synergistic action of vitamin-D and retinoic acid restricts invasion of macrophages by pathogenic mycobacteria. J Microbiol Immunol Infect 41:17–25PubMed
54.
Watts H, Lifeso R (1996) Tuberculosis of bones and joints. J Bone Joint Surg Am 78:288–298PubMed
55.
Hugosson C, Nyman R, Brismar J et al (1996) Imaging of tuberculosis. Peripheral osteoarticular and soft tissue tuberculosis. Acta Radiol 37:512–516PubMed
56.
Franco-Paredes C, Díaz-Borjon A, Senger M, Barragan L, Leonard M (2006) The ever-expanding association between rheumatologic diseases and tuberculosis. Am J Med 119:470–477PubMed
57.
Arthanari S, Yusuf S, Nisar M (2008) Tuberculosis of the knee complicating seronegative arthritis. J Rheumatol 35:1227–1228PubMed
58.
Kakourou T, Drosatou P, Psychou F, Aroni K, Nicolaidou P (2001) Erythema nodosum in children: a prospective study. J Am Acad Dermatol. 44:17–21PubMed
59.
Lowry K, Stephan K, Davis C (1999) Miliary tuberculosis presenting with rigors and developing unusual cutaneous manifestations. Cutis 64:23–28PubMed
60.
Elkayam O, Segal R, Lidgi M, Caspi D (2006) Positive anti-cyclic citrullinated proteins and rheumatoid factor during active lung tuberculosis. Ann Rheum Dis 65:1110–1112PubMed
61.
Teplizki H, Buskila D, Isenberg DA, Coates ARM, Sukenik S, Horowitz J, Shoenfeld Y (1987) Low serum anti-TB glycolipid antibodies titer in the sera of patients with SLE as an indicator of CNS involvement. J Rheumatol 14:507–511PubMed
62.
Zandman-Goddard G, Shoenfeld Y (2005) Infections and SLE. Autoimmunity 38:473–485PubMed
63.
Shoenfeld Y, Schwartz R (1984) Immunologic and genetic factors in autoimmune diseases. N Eng J Med 311:1019–1029CrossRef
64.
Blank M, Barzilai O, Shoenfeld Y (2007) Molecular mimicry and auto-immunity. Clin Rev Allergy Immunol 32:111–118PubMed
65.
Doria A, Canova M, Tonon M, Zen M et al (2008) Infections as triggers and complications of systemic lupus erythematosus. Autoimmun Rev 8:24–28PubMed
66.
Ortega-Hernandez OD, Agmon-Levin N, Blank M, Asherson RA, Shoenfeld Y (2009) The physiopathology of the catastrophic antiphospholipid (Asherson's) syndrome: compelling evidence. J Autoimmun 32:1–6PubMed
67.
Shoenfeld Y, Vilner Y, Coates A, Rauch J, Lavie G, Shaull D, Pinkhas J (1986) Monoclonal antituberculosis antibodies react with DNA, and monoclonal anti-DNA autoantibodies react with Mycobacterium tuberculosis. Clin Exp Immunol 66:255–261PubMed
68.
Holoshitz J, Koning F, Coligan J et al (1989) Isolation of CD4-CD8-mycobacteria-reactive T lymphocyte clones from rheumatoid arthritis synovial fluid. Nature 339:226–229PubMed
69.
Holoshitz J, Klajman A, Drucker I et al (1986) T lymphocytes of rheumatoid arthritis patients show augmented reactivity to a fraction of mycobacteria cross-reactive with cartilage. Lancet 2:305–309PubMed
70.
Pope R, Wallis R, Sailer D et al (1991) T cell activation by mycobacterial antigens in inflammatory synovitis. Cell Immunol 133:95–108PubMed
71.
Haftel H, Chang Y, Hinderer R et al (1994) Induction of the autoantigen proliferating cell nuclear antigen in T lymphocytes by a microbacterial antigen. Clin Invet 94:1365–1372
72.
George J, Shoenfeld Y, Gilburd B, Afek A, Shaish A, Harats D (2000) Requisite role for interleukin-4 in the acceleration of fatty streaks induced by heat shock protein 65 or Mycobacterium tuberculosis. Circ Res 86:1203–1210PubMed
73.
Winfield J (1989) Stress proteins, arthritis, and autoimmunity. Arthritis Rheum 32:1497–1504PubMed
74.
Jones D, Hunter N, Duff G (1990) Heat shock protein 65 as a β cell antigen of insulin dependent diabetes. Lancet 336:583–585PubMed
75.
Xu Q, Willeit J, Marosi M, Kleindienst R et al (1993) Association of serum antibodies to heat shock protein 65 with carotid atherosclerosis. Lancet 341:255–259PubMed
76.
Perschinka H, Mayr M, Millonig G et al (2003) Cross-reactive B-cell epitopes of microbial and human heat shock protein 60/65 in atherosclerosis. Arterioscler Thromb Vasc Biol 23:1060–1065PubMed
77.
Zhu J, Quyyumi A, Rott D et al (2001) Antibodies to human heat-shock protein 60 are associated with the presence and severity of coronary artery disease: evidence for an autoimmune component of atherogenesis. Circulation 103:1071–1075PubMed
78.
George J, Shoenfeld Y, Afek A, Gilburd B, Keren P, Shaish A, Kopolovic Y, Wick G, Harats D (1999) Enhanced fatty streak formation in C57BL/6J mice by immunization with heat shock protein 65. Arterioscler Thromb Vasc Biol 19:505–510PubMed
79.
Harats D, Yacov N, Gilburd B, Shoenfeld Y, George J (2002) Oral tolerance with heat shock protein 65 attenuates mycobacterium tuberculosis-induced and high-fat-diet-driven atherosclerotic esions. JACC 40:1333–1338PubMed
80.
Res P, Schaar C, Breedveld F et al (1988) Synovial fluid T cell reactivity against 65 kD heat shock protein of mycobacteria in early chronic arthritis. Lancet 27:478–480
81.
Tasneem S, Islam N, Ali R (2001) Crossreactivity of SLE autoantibodies with 70 kDa heat shock proteins of Mycobacterium tuberculosis. Microbiol Immunol 45:841–846PubMed
82.
Salvetti M, Buttinelli C, Ristori G et al (1992) T lymphocyte reactivity to the recombinant mycobacterial 65- and 70-kD heat shock proteins in multiple sclerosis. J Autoimmun 5:691–702PubMed
83.
Salvetti M, Ristori G, Buttinelli C et al (1996) The immune response to mycobacterial 70 kDa heat shock proteins frequently involves autoreactive T cells and is quantitatively disregulated in multiple sclerosis. J Neuroimmunol 65:143–153PubMed
84.
Alard J, Dueymes M, Youinou P, Jamin C (2007) Modulation of endothelial cell damages by anti-Hsp60 autoantibodies in systemic autoimmune diseases. Autoimmun Rev 6:438–443PubMed
85.
Gilbertson B, Germano S, Steele P et al (2004) Bystander activation of CD8+ T lymphocytes during experimental mycobacterial infection. Infect Immun 72:6884–6891PubMed
86.
Salgame P (2005) Host innate and Th1 responses and the bacterial factors that control Mycobacterium tuberculosis infection. Curr Opin Immunol 17:374–380PubMed
87.
Baccala R, Kono D, Theofilopoulos A (2005) Interferons as pathogenic effectors in autoimmunity. Immunol Rev 204:9–26PubMed
88.
Gardam M, Keystone E, Menzies R et al (2003) Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 3:148–155PubMed
89.
Keane J, Gershon S, Wise R et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345:1098–1104PubMed
90.
Tincani A, Andreoli L, Bazzani C, Bosiso D, Sozzani S (2007) Inflammatory molecules: a target for treatment of systemic autoimmune diseases. Autoimmun Rev 7:1–7PubMed
91.
Leadbetter E, Rifkin A, Hohlbaum A, Beaudette B et al (2002) Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416:603–607PubMed
92.
Rifkin I, Leadbetter E, Busconi L, Viglianti G, Marshak-Rothstein A (2005) Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 204:27–42PubMed
93.
Eriksson U et al (2003) Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med 9:1484–1490PubMed
94.
Waldner H, Collins M, Kuchroo V (2004) Activation of antigen-presenting cells by microbial products breaks self tolerance and induces autoimmune disease. J Clin Invest 113:990–997PubMed
95.
Deng G, Nilsson I, Verdrengh M et al (1999) Intra-articularly localized bacterial DNA containing CpG motifs induces arthritis. Nat Med 5:702–705PubMed
96.
Segal B, Chang J, Shevach E (2000) CpG oligonucleotides are potent adjuvants for the activation of autoreactive encephalitogenic T cells in vivo. J Immunol 164:5683–5688PubMed
97.
Lang K, Recher M, Junt T et al (2005) Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med 11:138–145PubMed
98.
Nishikubo K, Imanaka-Yoshida K, Tamaki S et al (2007) Th1-type immune responses by Toll-like receptor 4 signaling are required for the development of myocarditis in mice with BCG-induced myocarditis. J Autoimmun 29:146–153PubMed
99.
Silver K, Crockford T, Bouriez-Jones T et al (2007) MyD88-dependent autoimmune disease in Lyn-deficient mice. Eur J Immunol 37:2734–2743PubMed
100.
Sadanaga A, Nakashima H, Akahoshi M et al (2007) Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice. Arthritis Rheum 56:1618–1628PubMed
101.
Mansell A, Brint E, Gould J et al (2004) Mal interacts with tumor necrosis factor receptor-associated factor (TRAF)-6 to mediate NF-kappaB activation by toll-like receptor (TLR)-2 and TLR4. J Biol Chem 279:37227–37230PubMed
102.
Reiling N, Holscher C, Fehrenbach A et al (2002) Cutting edge: Toll-like receptor (TLR)2- and TLR4-mediated pathogen recognition in resistance to airborne infection with Mycobacterium tuberculosis. J Immunol 169:3480–3484PubMed
103.
Castiblanco J, Varela D, Castaño-Rodríguez N, Rojas-Villarraga A, Hincapié M, Anaya J (2008) TIRAP (MAL) S180L polymorphism is a common protective factor against developing tuberculosis and systemic lupus erythematosus. Infect Genet Evol 8:541–544PubMed
104.
Pearson C (1956) Development of arthritis, periarthritis, and periostitis in rats given adjuvant. Proc Soc Exp Biol Med 91:95–101PubMed
105.
Holoshitz J, Matitiahu A, Cohen I (1984) Arthritis induced in rats by cloned T-lymphocytes responsive to mycobacteria but not to collagen type II. J clin Invest 73:211–215PubMed
106.
Torisu M, Miyahara T, Shinohara N et al (1978) A new side effect of BCG immunotherapy: BCG-induced arthritis in man. Cancer Immunol Immunother 5:77–83
107.
Orbach H, Zandman-Goddard G, Amital H, Barak V, Szekanecz Z, Szucs G, Danko K, Nagy E, Csepany T, Carvalho JF, Doria A, Shoenfeld Y (2007) Novel biomarkers in autoimmune diseases: prolactin, ferritin, vitamin-D, and TPA levels in autoimmune diseases. Ann N Y Acad Sci 1109:385–400PubMed
108.
Carvalho JF, Blank M, Kiss E, Tarr T, Amital H, Shoenfeld Y (2007) Anti-vitamin-D, vitamin-D in SLE: preliminary results. Ann N Y Acad Sci 1109:550–557PubMed
109.
Cantorna M, Zhu Y, Froicu M, Wittke A (2004) Vitamin-D status, 1, 25-dihydroxyvitamin-D3, and the immune system. Am J Clin Nutr 80:1717S–1720SPubMed
110.
Ponsonby A-L, McMichael A, van der Mei I (2002) Ultraviolet radiation and autoimmune disease: insights from epidemiological research. Toxicology 181–182:71–78PubMed
111.
Pappa H, Gordon C, Saslowsky T et al (2006) Vitamin D status in children and young adults with inflammatory bowel disease. Pediatrics 118:1950–1961PubMed
112.
Nieves J, Cosman F, Herbert J, Shen V, Lindsay R (1994) High prevalence of vitamin-D deficiency and reduced bone mass in multiple sclerosis. Neurology 44:1687–1692PubMed
113.
Aguado P, del Campo M, Garces M et al (2000) Low vitamin-D levels in outpatient postmenopausal women from a rheumatology clinic in Madrid, Spain: their relationship with bone mineral density. Osteoporos Int 11:739–744PubMed
114.
Kamen D, Cooper G, Bouali H et al (2006) Vitamin-D deficiency in systemic lupus erythematosus. Autoimmun Rev 5:114–117PubMed
115.
Munger K, Levin L, Hollis B, Howard N, Ascherio A (2006) Serum 25-hydroxyvitamin-D levels and risk of multiple sclerosis. JAMA 296:2832–2838PubMed
116.
Abe J, Nakamura K, Takita Y, Nakano T, Irie H, Nishii Y (1990) Prevention of immunological disorders in MRL/l mice by a new synthetic analogue of vitamin D3: 22-oxa-1 alpha,25-dihydroxyvitamin-D3. J Nutr Sci Vitaminol 36:21–31PubMed
117.
Daniel C, Radeke H, Sartory N et al (2006) The new low calcemic vitamin-D analog 22-ene-25-oxa-vitamin-D prominently ameliorates Th1-mediated colitis in mice. J Pharmacol Exp Ther 319:622–631PubMed
118.
Cantorna M, Hayes C, DeLuca H (1996) 1, 25-Dihydroxyvitamin-D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 93:7861–8764PubMed
119.
Cantorna M, Humpal-Winter J, DeLuca H (1999) Dietary calcium is a major factor in 1, 25-dihydroxycholecalciferol suppression of experimental autoimmune encephalomyelitis in mice. J Nutr 129:1966–1971PubMed
120.
Mathieu C, Waer M, Laureys J, Rutgeerts O, Bouillon R (1994) Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin-D3. Diabetologia 37:552–558PubMed
121.
Munger K, Zhang S, O'Reilly E et al (2004) Vitamin-D intake and incidence of multiple sclerosis. Neurology 62:60–65PubMed
122.
Merlino L, Curtis J, Mikuls T et al (2004) Vitamin-D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum 50:72–77PubMed
123.
Cutolo M, Otsa K, Uprus M, Paolino S, Seriolo B (2007) Vitamin D in rheumatoid arthritis. Autoimmun Rev 7:59–64PubMed
124.
Goldberg P, Fleming M, Picard E (1986) Multiple sclerosis: decreased relapse rate through dietary supplementation with calcium, magnesium and vitamin-D. Med Hypotheses 21:193–200PubMed
125.
Birlea S, Costin G, Norris D (2008) Cellular and molecular mechanisms involved in the action of vitamin-D analogs targeting vitiligo depigmentation. Curr Drug Targets 9:345–359PubMed
126.
Hypponen E, Laara E, Reunanen A, Jarvelin M, Virtanen S (2001) Intake of vitamin D and risk of type 1 diabetes: a birthcohort study. Lancet 358:1500–1503PubMed
127.
Bhalla A, Amento E, Clemens T et al (1983) Specific high-affinity receptors for 1, 25-dihydroxyvitamin-D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab 57:1308–1310PubMed
128.
Provvedini D, Tsoukas C, Deftos L, Manolagas S (1986) 1 alpha, 25-Dihydroxyvitamin-D3-binding macromolecules in human B lymphocytes: effects on immunoglobulin production. J Immunol 136:2734–2740PubMed
129.
Chen S, Sims GP, Chen X et al (2007) Modulatory effects of 1, 25-dihydroxyvitamin-D3 on human B cell differentiation. J Immunol 179:1634–1647PubMed
130.
Doria A, Arienti S, Rampudda M, Canova M et al (2008) Preventive strategies in systemic lupus erythematosus. Autoimmun Rev 7:192–197PubMed
131.
Overbergh L, Decallonne B, Waer M et al (2000) 1alpha, 25-dihydroxyvitamin-D3 induces an autoantigen-specific T-helper 1/T-helper 2 immune shift in NOD mice immunized with GAD65 (p524–543). Diabetes 49:1301–1307PubMed
132.
Bhalla A, Amento E, Serog B, Glimcher L (1984) 1, 25-Dihydroxyvitamin-D3 inhibits antigen-induced T cell activation. J Immunol 133:1748–1754PubMed
133.
Lemire J (1992) Immunomodulatory role of 1, 25-dihydroxyvitamin-D3. J Cell Biochem 49:26–31PubMed
134.
Lemire J, Archer D, Beck L, Spiegelberg H (1995) Immunosuppressive actions of 1, 25-dihydroxyvitamin-D3: preferential inhibition of Th1 functions. J Nutr 125:1704S–1708SPubMed
135.
van Etten E, Mathieu C (2005) Immunoregulation by 1,25-dihydroxyvitamin-D3: basic concepts. J Steroid Biochem Mol Biol 97:93–101PubMed
136.
Ramos-Lopez E, Jansen T, Ivaskevicius V et al (2006) Protection from type 1 diabetes by vitamin-D receptor haplotypes. Ann N Y Acad Sci 1079:327–334PubMed
137.
Bailey R, Cooper J, Zeitels L et al (2007) Association of the vitamin-D metabolism gene CYP27B1 with type 1 diabetes. Diabetes 56:2616–2621PubMed
138.
Huang C, Wu M, Wu J, Tsai F (2002) Association of vitamin-D receptor gene BsmI polymorphisms in Chinese patients with systemic lupus erythematosus. Lupus 11:31–34PubMed
139.
Shimada A, Kanazawa Y, Motohashi Y et al (2008) Evidence for association between vitamin D receptor BsmI polymorphism and type 1 diabetes in Japanese. J Autoimmun 30:207–211PubMed
140.
Penna G, Amuchastegui S, Cossetti C et al (2006) Treatment of experimental autoimmune prostatitis in nonobese diabetic mice by the vitamin-D receptor agonist elocalcitol. J Immunol 177:8504–8511PubMed
141.
Penna G, Adorini L (2000) 1α,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 164:2405–2411PubMed
142.
Adorini L, Giarratana N, Penna G (2004) Pharmacological induction of tolerogenic dendritic cells and regulatory T cells. Semin Immunol 16:127–134PubMed
143.
Luciano A, Giuseppe P (2008) Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 4:404–412
144.
Shoenfeld Y, Selmi C, Zimlichman E, Gershwin ME (2008) The autoimmunologist: geoepidemilogy, a new center of gravity, and prime time for autoimmunity. J Autoimmun 31:325–30PubMed
145.
Adebajo A, Charles P, Maini R, Hazleman B (1993) Autoantibodies in malaria, tuberculosis and hepatitis B in a west African population. Clin Exp Immunol 92:73–76PubMed
146.
Flores-Suarez LF, Cabiedes J, Villa AR, van der Woude FJ, Alcocer-Varela J (2003) Prevalence of antineutrophilic cytoplasmatic autoantibodies in patients with tuberculosis. Rheumatology 42:223–229PubMed
147.
Sela O, el-Roeiy A, Isenberg DA, Kennedy RC, Colaco CB, Pinkhas J, Shoenfeld Y (1987) A common anti-DNA idiotype in sera of patients with active pulmonary tuberculosis. Arthritis Rheum 30:50–56PubMed
148.
Isenberg D, Maddison P, Swana G (1987) Profile of autoantibodies in the serum of patients with tuberculosis, klebsiella and other Gram-negative infections. Clin Exp Immunol 67:516–523PubMed
149.
Di Cesar D, Ploutz-Snyder R, Weinstock R, Moses A (2006) Vitamin D deficiency is more common in type 2 than in type 1 diabetes. Diabetes Care 29:174PubMed
Metadata
Title
Mycobacterium Tuberculosis, Autoimmunity, and Vitamin D
Authors
Yinon Shapira
Nancy Agmon-Levin
Yehuda Shoenfeld
Publication date
01-04-2010
Publisher
Humana Press Inc
Published in
Clinical Reviews in Allergy & Immunology / Issue 2-3/2010
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-009-8150-1

Other articles of this Issue 2-3/2010

Clinical Reviews in Allergy & Immunology 2-3/2010 Go to the issue

OriginalPaper

The Premenstrual Syndrome and Fibromyalgia—Similarities and Common Features

OriginalPaper

Currents Concepts on the Immunopathology of Amyloidosis

OriginalPaper

Efficacy and Safety of Anti-Tumour Necrosis Factor in Elderly Patients with Rheumatoid Arthritis: An Observational Study

OriginalPaper

Immunogenicity of Anti-TNF-α Agents in Autoimmune Diseases

OriginalPaper

Pregnancy and Systemic Lupus Erythematosus: Review of Clinical Features and Outcome of 51 Pregnancies at a Single Institution

OriginalPaper

High-Dose Intravenous Immunoglobulin (IVIG) Therapy in Autoimmune Skin Blistering Diseases
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits